Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

03 Jun, 2025, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib (CPI-0610), Dencatistat (STP 938), INCA033989, and VAC85135.

LAS VEGAS, June 3, 2025 /PRNewswire/ -- Essential thrombocythemia is a chronic form of myeloproliferative neoplasm (MPN) marked by an abnormally high platelet count in the bloodstream. It is most frequently diagnosed in women over 50 and involves the excessive production of platelet precursors in the bone marrow. Common complications include blood clots and bleeding, while less frequent but more serious outcomes in advanced stages can involve progression to myelofibrosis or acute leukemia.

As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about 75% of these cases linked to mutations in the JAK2 gene. During the same year, an estimated 85K patients in the US received first-line treatment for essential thrombocythemia.

The primary goal of essential thrombocythemia management is to reduce the risk of vascular complications, such as thrombotic and hemorrhagic events, which are major contributors to illness and death. Treatment approaches are guided by a risk stratification system that classifies patients as either low or high risk for thrombosis. Typically, low-risk individuals are younger and have no history of clotting events, while high-risk patients are generally over 60 years old and have experienced thrombosis in the past.

Learn more about the essential thrombocythemia cancer @ New Treatment for Essential Thrombocythemia

For low-risk patients, aspirin is recommended, provided there are no major contraindications. However, caution is advised when platelet counts exceed 1,000 × 10⁹/L, as this raises the risk of acquired von Willebrand disease. In such cases, if laboratory findings suggest von Willebrand abnormalities, aspirin should be avoided. Aspirin is also the preferred treatment in patients experiencing microvascular complications like erythromelalgia. 

In contrast, high-risk patients are typically managed with a combination of antiplatelet and cytoreductive therapies. Hydroxyurea is generally considered the first-line agent for cytoreduction. However, anagrelide may be used as an alternative when hydroxyurea is poorly tolerated or ineffective.

At present, only one drug is officially approved for the treatment of essential thrombocythemia, and its use is restricted to Europe. There are currently no FDA-approved therapies for essential thrombocythemia in the United States. PEGASYS, a Type I interferon, is made by pegylating interferon alfa-2a, which involves attaching polyethylene glycol (PEG) chains to the molecule. 

Find out more on FDA-approved essential thrombocythemia drugs @ Essential Thrombocythemia Treatment Options

PEGASYS was previously approved by the European Commission (EC) for treating Chronic Hepatitis B in adults and children over 3, and Chronic Hepatitis C in adults and children over 5, in combination with other medications. In August 2024, pharmaand GmbH announced that the EC had granted a Type II variation approval for PEGASYS, allowing its use as a monotherapy for adults with essential thrombocythemia.

Various key players are leading the treatment landscape of essential thrombocythemia, such as pharma&, AOP Orphan Pharmaceuticals AG, Merck Sharp and Dohme, Novartis, Incyte Corporation, and others.

Discover which therapies are expected to grab major essential thrombocythemia market share @ Essential Thrombocythemia Market Report

Bomedemstat (MK-3543) is an experimental small-molecule drug developed by Merck that irreversibly inhibits LSD1, a key regulator of hematopoietic stem cell proliferation, differentiation, and maturation. The drug is under clinical evaluation for various myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera.

In 2018, Bomedemstat was granted Orphan Drug Designation (ODD) for essential thrombocythemia treatment. In January 2020, Imago BioSciences received Fast Track Designation (FTD) from the US FDA for bomedemstat for the same indication.

By November 2022, Merck announced its acquisition of Imago BioSciences, a clinical-stage biotechnology company focused on bomedemstat for myelofibrosis treatment, for $36 per share in cash, totaling approximately $1.35 billion. This strategic move aimed to strengthen Merck's hematology portfolio and establish its presence in the growing myelofibrosis market.

PharmaEssentia is advancing ropeginterferon alfa-2b (P1101) for essential thrombocythemia, offering a biweekly injection regimen aimed at improving tolerability and patient adherence, thereby enhancing therapeutic outcomes. A global Phase III clinical trial for essential thrombocythemia is currently in progress. Participants who respond positively during the initial study period will continue into an extension phase for long-term evaluation.

Pelabresib, another investigational therapy, is a selective small molecule targeting BET (bromodomain and extra-terminal domain) proteins, which are involved in gene regulation associated with hematologic malignancies. The ongoing Phase II MANIFEST trial (NCT02158858) is assessing its efficacy in patients with myelofibrosis and high-risk ET through an open-label study.

In February 2024, MorphoSys entered into a Business Combination Agreement with Novartis AG, reflecting Novartis's plan to launch a voluntary public takeover offer for all outstanding MorphoSys bearer shares without nominal value.

Discover more about drugs for essential thrombocythemia in development @ Essential Thrombocythemia Clinical Trials

The anticipated launch of these emerging therapies for essential thrombocythemia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the essential thrombocythemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

DelveInsight estimates that the market size for essential thrombocythemia is expected to grow from USD 417 million in the 7MM in 2024 at a significant CAGR by 2034. The market size of essential thrombocythemia is expected to grow due to several factors, including an increase in the prevalent pool, the expected entry of emerging therapies with novel targets, and attractive pricing in the 7MM.

DelveInsight's latest published market report, titled as Essential Thrombocythemia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the essential thrombocythemia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The essential thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases
  • Symptom-specific Cases
  • Gender-specific Cases
  • Mutation-specific Cases
  • Risk-specific Cases
  • Age-specific Cases
  • Total Treated Cases

The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM essential thrombocythemia market. Highlights include:

  • 10-year Forecast
  • 7MM Analysis
  • Epidemiology-based Market Forecasting
  • Historical and Forecasted Market Analysis upto 2034
  • Emerging Drug Market Uptake
  • Peak Sales Analysis
  • Key Cross Competition Analysis
  • Industry Expert's Opinion
  • Access and Reimbursement

Download this essential thrombocythemia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the essential thrombocythemia market. Also, stay abreast of the mitigating factors to improve your market position in the essential thrombocythemia therapeutic space.

Related Reports

Essential Thrombocythemia Epidemiology

Essential Thrombocythemia Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the essential thrombocythemia epidemiology trends.

Essential Thrombocythemia Pipeline

Essential Thrombocythemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key essential thrombocythemia companies, including PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals, among others.

Polycythemia Vera Market

Polycythemia Vera Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera companies, including IIncyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others.

Polycythemia Vera Pipeline

Polycythemia Vera Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycythemia vera companies, including Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight

Angelman syndrome is a rare neurogenetic disorder affecting approximately 1 in 15,000 live births or 500,000 people globally. It results from the...

INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight

INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight

DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.